Sebiprox 1.5%

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sebiprox 1.5%

Property Description
Active ingredient Ciclopirox (INN)
Form Shampoo Solution
Pharmacological Class Topical Antifungal (Hydroxypyridone)
Origin Synthetic Compound
General Purpose Microbial control on the skin and scalp

What Type of Medicine is Sebiprox 1.5% and How is it Classified?

Sebiprox 1.5% is a specifically formulated pharmaceutical preparation classified as a topical antifungal agent. It is designed as a specialized shampoo solution intended for cutaneous use on the skin and scalp. The medication belongs to the Hydroxypyridone chemical family, a distinct subgroup within the broader class of Antifungal Agents for dermatological use. This classification confirms the product’s function as a medicine designed to target biological causes rather than simply a cosmetic or cleansing agent. Hydroxypyridone derivatives, including Ciclopirox, are recognized for their efficacy against a range of dermatophytes and yeasts.


Composition and Origin: Is Ciclopirox a Natural or Synthetic Ingredient?

The core therapeutic component in Sebiprox 1.5% is the active ingredient Ciclopirox (INN), which is a synthetic, single-component compound. The medication contains Ciclopirox, often present as the salt Ciclopirox Olamine, in a fixed 1.5% concentration within its aqueous shampoo base. This concentration is clinically recognized as effective for its intended purpose against fungal overgrowth. Ciclopirox is derived from the hydroxypyridone chemical structure, confirming its synthetic origin. The 1.5% designation strictly indicates the strength of the active substance within the solution.


General Purpose and How it Helps the Scalp

The general purpose of Sebiprox 1.5% is to achieve microbial control on the scalp by targeting and reducing the presence of susceptible fungi and yeast. Ciclopirox works by disrupting the fungal cell’s internal operations, giving it properties that are both fungistatic (it stops the growth of the fungus) and, at effective concentrations, fungicidal (it kills the fungus). For instance, the specialized shampoo formulation is used to address the scaling and flaking associated with common conditions where yeast overgrowth is a factor. Additionally, Ciclopirox is known to possess inherent mild anti-inflammatory properties, which can assist in calming associated skin irritation and discomfort, promoting a healthier scalp environment.

Regulatory References

  1. NIH MedlinePlus Drug Information for Ciclopirox Topical

What side effects are possible with Sebiprox 1.5%?

Possible Side Effects and Safety Information

The safety profile of Sebiprox 1.5% (Ciclopirox) shampoo is based on regulatory documents and clinical experience, with most reported effects relating to the site of application on the scalp. Adverse reactions are classified by frequency as defined in official regulatory standards.


Frequency Classifications of Adverse Reactions

The majority of side effects are classified under Skin and subcutaneous tissue disorders.

Classification Adverse Reaction (SOC Terminology)
Very Common (≥ 1 in 10 users) Pruritus (itching), Skin irritation
Common (≥ 1 in 100 to < 1 in 10 users) Burning sensation, Erythema (redness), Rash
Rare (≥ 1 in 10,000 to < 1 in 1,000 users) Allergic reaction, Skin exfoliation (flaking), Eczema, Alopecia (hair loss), Hair colour/texture changes

Serious Adverse Reactions officially documented relate to Immune system disorders, including severe allergic reactions or hypersensitivity.


Safety Considerations and Constraints

A core Contraindication listed in regulatory information is a known hypersensitivity to the active ingredient, ciclopirox olamine, or to any other component in the shampoo formulation.

Population-Specific Notes: Safety and effectiveness for this formulation have not been established in subjects younger than 16 years of age. Regarding pregnancy and nursing mothers, use requires caution as there are no adequate, well-controlled studies, although systemic absorption is noted to be low. The rare occurrence of hair colour and texture changes is noted to be more likely in patients with grey, white, or chemically damaged hair.

Overdose and Emergency Response

The official regulatory documentation for Sebiprox 1.5% (Ciclopirox Shampoo), a product intended solely for external cutaneous use, defines the overdose profile primarily around the risk of accidental oral ingestion. Due to the low systemic absorption of the active ingredient following external application, the occurrence of systemic toxicity from topical overuse is officially considered unlikely. Regulatory labeling contains no specific documentation for systemic symptom clusters resulting from topical over-application.

When to Seek Immediate Help

In the event of a suspected or confirmed overdose, the primary official mandate is to seek immediate medical attention. This action is required even if the affected individual is not displaying symptoms of distress. The necessary steps, as described in government regulatory documents, include:

  • Contacting a regional Poison Control Centre or a hospital emergency department immediately.
  • Management for accidental ingestion is defined as symptomatic and supportive treatment, including appropriate clinical monitoring, as no specific antidote is known.
  • For cases of accidental contact with the eyes or mucous membranes, the required procedure is to rinse thoroughly with copious amounts of water.

Therapeutic Uses of Sebiprox 1.5%

What Sebiprox 1.5% Treats: Main Uses and Benefits

Sebiprox 1.5% cutaneous solution is used to assist in the management of symptoms associated with seborrhoeic dermatitis of the scalp. This condition may present with noticeable signs such as flaking, scaling, and itchiness. The medication is helpful in clinical scenarios where the patient experiences these symptoms due to the proliferation of specific yeasts on the scalp. The active ingredient, ciclopirox olamine, supports the control of these scalp issues.

A main benefit reported by patients is help with managing irritating symptoms, such as persistent itching and visible scaling associated with these common scalp conditions. The goal of treatment is to support the management of the signs of scalp dermatitis. Indications include the management of flaking, scaling, redness, and itching of the scalp. It is an option that can help manage the uncomfortable signs of seborrhoeic dermatitis.

Quick Fact: Relief for Scalp Itch and Flaking

Regulatory References

  1. MHRA product information for Sebiprox 1.5% cutaneous solution

Eligibility and Restrictions for Use

Who Can and Cannot Use Sebiprox 1.5%? (Official Eligibility)

Official regulatory documents define the eligible and non-eligible populations for Sebiprox 1.5% (ciclopirox olamine) shampoo, primarily based on contraindications, age restrictions, and reproductive status.

Eligibility Constraints

Population Status Regulatory Rule Implication
Contraindicated Known hypersensitivity/allergy to ciclopirox olamine or any other component of the formulation. Must Not Use
Pediatric Use Safety and efficacy have not been established in children (e.g., typically under 16 or 18 years, depending on the document). Use is Not Recommended/Restricted to Adults
Pregnancy Safety not established in human pregnancy; studies are insufficient. Use Only If Clearly Needed and benefit justifies potential risk
Lactation Unknown whether the drug is excreted in human milk; systemic exposure is low. Caution Advised; ensure product is washed off the breast prior to nursing

Sebiprox 1.5% is intended for external use only on the scalp. Individuals with a documented allergy to the active ingredient are formally contraindicated from using this medicine. Due to a lack of clinical data, its use is generally restricted to the adult population. Pregnant and breastfeeding women should exercise caution, as official safety data for human reproductive exposure are limited.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documentation for Sebiprox 1.5% (ciclopirox) topical formulations, such as the shampoo, cream, or gel, generally indicates that there are no known or documented systemic drug-drug interactions. This is primarily attributed to the very low systemic absorption of the active ingredient, ciclopirox, when applied to the skin or scalp as intended.

Since minimal amounts of the medication enter the bloodstream, the likelihood of the drug interfering with the metabolism or effectiveness of oral or injected systemic medications is considered low. Consequently, regulatory documents do not typically list specific interacting medicines or require mandatory time separation from other drug administrations.

However, a specific precaution is noted in the official labeling for a different, higher-concentration ciclopirox formulation (the 8% nail lacquer) used for onychomycosis. For that product, co-administration with systemic antifungal agents for treating nail infections is not recommended. This advisory stems from a lack of clinical studies determining whether ciclopirox may potentially reduce the efficacy of the systemic antifungal treatment when used concurrently.

While this constraint relates to a separate formulation, it represents the primary interaction-related note within the product family. For the Sebiprox 1.5% topical preparation, users should consult a healthcare professional regarding any planned concurrent use of other topical products on the same application area.

Mechanism of Action

Disruption of Fungal Energy and Metabolic Integrity

The active ingredient, Ciclopirox, exerts its primary action by chelating and binding to vital polyvalent cations, such as ferric iron ( Fe^3+), which are essential cofactors for numerous fungal enzymes. This rapid sequestration of Fe^3+ directly inhibits the fungal mitochondrial electron transport chain and prevents the proper function of oxidative stress enzymes like catalase. This unique, multi-target molecular interference starves the fungal cells of energy (ATP) and disrupts protein/DNA synthesis, leading to a profound loss of microbial viability and suppression of fungal reproduction.

Modulation of Local Skin Inflammation

In addition to its anti-microbial effect, Ciclopirox possesses a complementary mechanism of action by modulating the host's own inflammatory response at the site of application. The molecule acts as an inhibitor of the enzyme 5-Lipoxygenase (5-LOX), which is critical in the arachidonic acid cascade. By blocking 5-LOX, the production of potent inflammatory mediators called Leukotrienes is reduced. This leads to the physiological consequence of a reduced local inflammatory response, contributing to a local dampening of the host's physiological activity in the tissue.

Dosage and Administration Information

How to Use Sebiprox 1.5% (Ciclopirox Shampoo)

Sebiprox 1.5% is a topical prescription medication used according to a defined, high-level regimen. The instructions detail the method, frequency, dosage volume, and duration required for standardized use.

Official Administration Protocol

The medication is designed exclusively for topical use, meaning external application to the hair and scalp. It is available as a shampoo solution containing Ciclopirox at a 1.5% concentration, though a 1% concentration exists in other regions.

Feature Official Usage Standard
Route of Administration Cutaneous (on the scalp only)
Standard Volume Approximately 5 mL (1 teaspoon); up to 10 mL for longer hair
Frequency Twice per week
Interval A minimum of 3 days must pass between applications
Duration Initial treatment course is typically 4 weeks

Step Sequence and Contact Time

Proper use of the solution is structured by specific procedural steps. The hair must be wet before the shampoo is applied to the scalp. After application, the solution should be gently massaged to produce a lather. A 3-minute contact time is required, during which the lather must remain on the scalp before it is thoroughly rinsed off with water. The entire treatment regimen is indicated for use in adults and adolescents 16 years and older.

Recent Clinical Evidence

Research evidence / Overview of Studies for Sebiprox 1.5%

Evidence for use in Seborrhoeic Dermatitis of the Scalp

The research exploring Ciclopirox 1.5% (the active ingredient in Sebiprox 1.5% shampoo) primarily focuses on outcomes related to seborrhoeic dermatitis of the scalp. The research base consists mainly of short-term Randomized Controlled Trials (RCTs). These studies were conducted to explore how symptoms change over time and often compared the active ingredient against a non-active vehicle (placebo) or against other active antifungal therapies. This approach is used in research examining patient-reported experiences and clinical observations relevant in trials assessing short-term or episodic symptom patterns.

Research monitored outcomes related to physical discomfort. Researchers examined objective clinical signs, such as the amount of scaling and redness (erythema) on the scalp, which are outcomes linked to inflammatory or irritative states. Additionally, studies monitored patient-reported outcomes describing perceived discomfort, focusing particularly on changes in scalp itching (pruritus) experienced by the observed populations. Research also explored outcomes related to scalp microbial status by examining the count of Malassezia yeast, as an outcome related to the condition's biological characteristics.

Long-Term Studies and Durability of Findings

Most of the available research examining Ciclopirox 1.5% is relevant in trials assessing short-term symptom patterns, with active treatment periods typically lasting about four weeks. The evidence derived from these settings provides insight into short-term changes during studies conducted during periods of increased symptom activity.

However, data are still emerging regarding the sustained outcome after the treatment phase. Follow-up durations were limited in many studies, and there is limited information for long-term outcomes. Some research examined patterns related to the return of symptoms (relapse) after the active treatment phase was stopped. Long-term effects are not fully established, and certainty remains low regarding sustained remission.

Research Gaps and Areas of Uncertainty

The certainty remains low regarding the generalizability of findings across all possible populations, as sample sizes were modest in some trials and results apply only to the groups studied. One key gap is the limited information available regarding long-term outcomes and the long-term status of symptoms. Comparative evidence is lacking in certain scenarios, and evidence quality varies across studies, indicating that research is ongoing in certain areas.

Key Studies & References

  1. Topical Antifungal Agents for Seborrheic Dermatitis: Systematic Review and Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about Sebiprox 1.5% (FAQ)

Q: What conditions, besides dandruff, is Sebiprox 1.5% approved to treat?

A: According to official product information, Sebiprox 1.5% is primarily indicated for the topical treatment of seborrhoeic dermatitis of the scalp. Seborrhoeic dermatitis is a common condition that can cause scaling, flaking, and redness. The drug is indicated for the purpose of microbial control associated with this condition.

Q: Is Sebiprox 1.5% considered a steroid or an anti-fungal treatment?

A: Official regulatory documents classify Sebiprox 1.5% as a topical antifungal agent. Its active ingredient, Ciclopirox, belongs to a chemical family called Hydroxypyridone. The product is not a steroid and works by disrupting the internal functions of the yeast and fungi on the scalp.

Q: How long does it usually take before I might notice an effect from Sebiprox 1.5%?

A: Official prescribing information indicates that the initial treatment course is typically around four weeks. Regulatory documents note that if no clinical improvement is observed after 4 weeks of treatment, the diagnosis should be reviewed, which provides the timeframe for expected evaluation.

Q: Is Sebiprox 1.5% safe to use while pregnant or breastfeeding, according to official guidance?

A: Official guidance states that safety has not been established in human pregnancy due to a lack of adequate studies. Use requires caution, and it should only be used if the potential benefit justifies the potential risk. For breastfeeding, caution is advised because it is unknown whether the drug is excreted in human milk, even though systemic exposure is low.

Q: What happens if Sebiprox 1.5% gets into my eyes?

A: Official warnings and precautions state that contact with the eyes should be avoided. If accidental contact does occur, the affected area should be rinsed well and immediately with water.

Q: What if I accidentally swallow a small amount of Sebiprox 1.5%?

A: Official information states the ingredients are not expected to pose harm if swallowed in very small amounts. If accidental ingestion occurs, the mouth should be rinsed with water. In the event a large amount is swallowed, advice from a healthcare professional should be sought.

Q: Can I use Sebiprox 1.5% if I have an open cut or wound on my scalp?

A: The medication is intended for topical use only. Official warnings advise that if a reaction suggesting sensitivity or irritation occurs, the treatment should be discontinued. Some regulatory documents specify avoiding application to broken, abraded, or irritated skin.

Q: Is the active ingredient in Sebiprox 1.5% absorbed into the bloodstream?

A: Studies summarized in official documents indicate that the systemic absorption of the active ingredient, Ciclopirox, when applied to the scalp as directed, is very low. This low absorption is why interactions with medicines taken by mouth are considered unlikely.

Q: If I stop using Sebiprox 1.5%, will my symptoms immediately return?

A: Research summaries in regulatory documents mention that long-term effects are not fully established, and there is limited data concerning the sustained outcome after the full treatment course has been stopped. Some research has examined patterns related to the return of symptoms after treatment ends, but official information states that certainty is low regarding the sustained status of symptoms.

Q: Are there any known interactions between Sebiprox 1.5% and hair dyes or color treatments?

A: While the drug is not known to interact systemically with topical hair dyes, official documents list a rare side effect of hair colour/texture changes. This is noted to be more likely in patients with grey, white, or chemically damaged hair.

Q: Why is Sebiprox 1.5% sometimes prescribed over over-the-counter options?

A: The drug is classified as a prescription medicine because its active ingredient, Ciclopirox, has a unique mechanism of action. This involves targeting fungal growth by chelating cations and possessing anti-inflammatory properties that differentiate it from many standard over-the-counter alternatives.

Q: Does Sebiprox 1.5% interact with common oral supplements?

A: Because of the very low systemic absorption, the likelihood of the drug interfering with the metabolism of oral medications or supplements is considered low. However, general regulatory guidance emphasizes the importance of informing a healthcare provider of all products being used, including vitamins and herbal supplements.

Q: Are there special considerations for older adults (seniors) using Sebiprox 1.5%?

A: Safety and effectiveness have been established for the adult population in general. However, some regulatory documents state that it is not known if the medication is safe and effective in adults over 65 years old, which reflects a lack of specific studies for this older age group.

Q: Is it okay to use Sebiprox 1.5% on other areas of the body besides the scalp?

A: No. Regulatory labeling for the product specifies that it is indicated for the topical treatment of seborrhoeic dermatitis of the scalp in adults. It is strictly labeled for 'external use on the scalp only.'

Q: Can Sebiprox 1.5% be used in conjunction with moisturizing conditioners?

A: The official use instructions focus on rinsing the shampoo thoroughly with water. There are no specific restrictions listed in the core documents regarding the immediate follow-up use of topical products like conditioners after rinsing.

Q: Does Sebiprox 1.5% treat the underlying cause of the condition or just the symptoms?

A: The medication is described as having properties that are both fungicidal (killing the fungus) and fungistatic (stopping the growth of the fungus), which addresses the underlying microbial cause. Additionally, it has inherent mild anti-inflammatory properties to help calm associated symptoms like irritation and redness. Therefore, it is described as addressing both the cause and associated symptoms.

Q: What is the difference between Sebiprox 1.5% and other common anti-dandruff shampoos?

A: Sebiprox 1.5% is a prescription-strength medication containing the active ingredient Ciclopirox, which is a hydroxypyridone antifungal. This gives it a unique, dual mechanism of action targeting both the fungal component and inflammation, unlike many common over-the-counter shampoos that typically use different active ingredients.

Q: Does research show Sebiprox 1.5% is more effective for certain hair types?

A: Research summaries in regulatory documents state that the certainty remains low regarding the generalizability of findings across all possible populations. This is because study sample sizes were modest in some trials, meaning specific differences in effectiveness related to hair type were not the focus of the primary research.

Q: If I have sensitive skin, is Sebiprox 1.5% likely to cause a reaction?

A: Official documents list common side effects such as skin irritation and a burning sensation at the application site. For individuals with sensitive skin, it is also noted that the product is contraindicated (must not be used) if there is a known hypersensitivity or allergy to any of its components.

Q: Why do some people experience temporary dry hair when using Sebiprox 1.5%?

A: Official regulatory documents list hair disorders, which can include changes in hair structure leading to dry, dull, or brittle hair, as a rare adverse reaction that has been reported.

Q: Can I use Sebiprox 1.5% if I have a history of eczema?

A: Official regulatory documents list the worsening of pre-existing skin conditions, such as eczema, as a rare adverse reaction observed during the use of this medication.

How should Sebiprox 1.5% be stored and disposed of?

How to Store and Dispose of Sebiprox 1.5% Shampoo

Official regulatory guidance defines the following requirements for storing and discarding Sebiprox 1.5% (Ciclopirox Olamine) solution.


Storage and Stability

  • Child Protection: The medication must be kept out of the reach and sight of children to prevent accidental use.
  • Environmental Storage: No special precautions for storage are required, simplifying temperature and environmental constraints.
  • Shelf-Life: Do not use the shampoo after the expiry date shown on the bottle and the outer packaging.

Disposal Instructions

  • Waste Exclusion: The product must not be disposed of via wastewater or household waste to protect the environment.
  • Procedure: Users must ask their pharmacist how to dispose of unused or expired medicines that are no longer required.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sebiprox 1.5% found in:

A-Z Index: